OBJECTIVE: The study was conducted to evaluate and compare the effect of insulin sensitizers
i.e. metformin and myoinositol on anthropometric parameters in patients of the Polycystic
ovarian syndrome (PCOS). STUDY DESIGN: Comparative study METHODS: Comparative,
clinical study was conducted on 120 patients at kishwar fazal teaching hospital sheikhupura,
from April 2018 to June 2019. The patients were randomly divided into two groups having 60
females in each group, two treatments (Tab Myoinositol and Tab Metformin) were given: group
A: Tablet myoinositol 1000 twice daily. group B: Tablet metformin 500 mg three times a day for
24 weeks. Anthropometric parameters were assessed by measuring body weight, Body mass
index (BMI), waist-hip ratio (WHR) at the start of study i,e baseline and subsequently at the end
of 12 week and 24 weeks. RESULTS: In both groups, the improvement was seen over a
period of 24 week. In group A, the values for weight at baseline, 12 week and 24 week expressed in mean±SEM are 65.86±.80, 64.30±.78 and 63.10±.55 while in group B the values were
65.98±.99, 64.33±1.74 and 63.20±1.45. In group A, BMI at baseline, 12 week and 24 week was
26.45±.41, 25.78±.42 and 25.31±.40 while in group B the values were 27.56±.41, 26.58±.32 and
26.43±.70 respectively. In group A, WHR was 0.77±.007, 0.76±.005 and 0.76±.007 while in
group B 0.78±.008, 0.77±0.88, 0.77±.011 at baseline, 12 w and 24 w respectively. However, no
statistically significant difference was observed in all the parameters. CONCLUSION: The
definitive improvement seen in anthropometric parameters with both metformin and myoinositol
but on comparing these drugs, no significant difference was observed. Thus, myoinositol can
also be used as an alternative to metformin for the treatment of PCOS.
Keywords: PCOS, BMI, WHR, Myo-inositol, Metformin, Anthropometric
Publication date: 01/02/2020
https://ijbpas.com/pdf/2020/February/MS_IJBPAS_2020_4950.pdf
Download PDF
https://doi.org/10.31032/IJBPAS/2020/9.2.4950
